Literature DB >> 29337219

Citrus bioflavonoid, hesperetin, as inhibitor of two thrombin-like snake venom serine proteases isolated from Crotalus simus.

Roney Vander Dos Santos1, Fabian Villalta-Romero2, Danijela Stanisic1, Luiz Borro3, Goran Neshich4, Ljubica Tasic5.   

Abstract

Around 5.5 million people suffer from snakebites per year, with about 400,000 cases with some type of sequelae, such as amputation, and 20,000 to 125,000 cases with the fatal end. Usually, the victim outcome depends on correct, agile and many times in situ intervention based on the proper identification of the snake venom type and its potential effects, among other factors. Therefore, knowledge on the snake venom composition and a research on inhibitors of snake venom target components might ameliorate envenoming dangerous outcome. Herein, two thrombin-like serine proteases from the Crotalus simus snake venom - SVSP1 and SVSP2 - were isolated in two chromatographic steps, using gel filtration and then RP-HPLC. They showed molecular masses of around 31.3 and 24.6 kDa, respectively, and mostly β-sheet secondary structure features. The SVSP1 and SVSP2 were sequenced using tandem mass spectrometry (Q-TOF). Using the known serine protease structure (PDB entry: 4e7n), which was evaluated as homologous to the two target proteins, in silico docking results showed that hesperetin is its excellent inhibitor. Using in vitro tests with the commercial hesperetin, kinetic parameters were obtained for SVSPs against the synthetic substrate BApNA. Obtained results pointed that hesperetin might act as an uncompetitive (SVSP1) or mixed (SVSP2) inhibitor. Also, the fluorescence quenching upon inhibition was observed, as well as, red shift in maximums of around 20 nm, which indicate that the tryptophan residues in the target enzymes suffered conformational changes caused by hesperetin binding. Thus, a naturally occurring flavone that can easily be extracted from oranges might serve as low-cost inhibitor of the investigated snake venom proteases.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crotalus simus; Enzymes inhibition; Hesperetin; Snake venom serine proteases (SVSPs); in silico and in vitro analyses

Mesh:

Substances:

Year:  2018        PMID: 29337219     DOI: 10.1016/j.toxicon.2018.01.005

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

Review 1.  Plant-Derived Toxin Inhibitors as Potential Candidates to Complement Antivenom Treatment in Snakebite Envenomations.

Authors:  Asenate A X Adrião; Aline O Dos Santos; Emilly J S P de Lima; Jéssica B Maciel; Weider H P Paz; Felipe M A da Silva; Manuela B Pucca; Ana M Moura-da-Silva; Wuelton M Monteiro; Marco A Sartim; Hector H F Koolen
Journal:  Front Immunol       Date:  2022-05-09       Impact factor: 8.786

2.  In vitro study of Hesperetin and Hesperidin as inhibitors of zika and chikungunya virus proteases.

Authors:  Raphael J Eberle; Danilo S Olivier; Carolina C Pacca; Clarita M S Avilla; Mauricio L Nogueira; Marcos S Amaral; Dieter Willbold; Raghuvir K Arni; Monika A Coronado
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

3.  A First Look at the Inhibitory Potential of Urospatha sagittifolia (Araceae) Ethanolic Extract for Bothrops atrox Snakebite Envenomation.

Authors:  Antonio L Vera-Palacios; Juan D Sacoto-Torres; Josselin A Hernández-Altamirano; Andres Moreno; Maria C Peñuela-Mora; David Salazar-Valenzuela; Noroska G S Mogollón; José R Almeida
Journal:  Toxins (Basel)       Date:  2022-07-17       Impact factor: 5.075

Review 4.  Research progress on the mechanism of action of hesperetin in cerebral ischemia: a narrative review.

Authors:  Qingchun Mu; Yufei Zhang; Qian Cheng; Hanning Huang; Chunming Huang; Longguang Tang
Journal:  Ann Transl Med       Date:  2022-07

5.  Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.

Authors:  Haixin Li; Ying Huang; Xian Wu; Ting Wu; Ying Cao; Qimei Wang; Yuchang Qiu; Weiming Fu; Qun Zhang; Jianxin Pang
Journal:  Drug Des Devel Ther       Date:  2018-05-23       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.